Enveric Biosciences, Inc. (ENVB) — DEF 14A Filings
All DEF 14A filings from Enveric Biosciences, Inc.. Browse 4 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (4)
-
Enveric Seeks Reverse Split, Massive Share Increase to Boost Stock, Funding
— Oct 27, 2025 Risk: high
Enveric Biosciences, Inc. (ENVB) is holding a Special Meeting on December 11, 2025, to address critical financial and operational challenges. The company seeks -
Enveric Biosciences DEF 14A: Executive Pay Revealed
— Apr 15, 2025 Risk: medium
Enveric Biosciences, Inc. filed a DEF 14A on April 15, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes -
Enveric Biosciences Files Definitive Proxy Statement
— Dec 18, 2024 Risk: low
Enveric Biosciences, Inc. filed its definitive proxy statement on December 18, 2024, for its annual meeting. The company, previously known as Ameri Holdings, In -
Enveric Biosciences Announces 2024 Annual Meeting of Stockholders
— Apr 16, 2024 Risk:
Enveric Biosciences, Inc. (ENVB) filed a Proxy Statement (DEF 14A) with the SEC on April 16, 2024. The 2024 Annual Meeting of Stockholders for Enveric Bioscienc
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX